iSpecimen (ISPC) stock price, chart and financials
Price chart
Financials
- Revenue (trailing twelve months)
- $466,302.00
- Revenue (quarter)
- $151,940.00
- Gross profit (trailing twelve months)
- −$504,830.00
- Gross margin
- −108.26%
- Net income (quarter)
- −$1.4M
- Net margin
- −2449.04%
- Return on equity
- −968.47%
- EPS (trailing twelve months)
- −$50.48
- Book value per share
- $1.14
- Price to book
- 1.57
- Debt to assets
- 76.51%
Company profile
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
Frequently asked questions
Is iSpecimen (ISPC) profitable?
No. iSpecimen reported a net loss of $11.4M over the trailing twelve months.
How much revenue does iSpecimen (ISPC) make?
iSpecimen generated $466,302.00 in revenue over the trailing twelve months, down 78.69% year over year.
How do I buy stock in iSpecimen (ISPC)?
ISPC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.